Clinical trial of anti-CTLA4 on GBMa
| Clin. Trial ID | Disease | Interventions | Status | Phase | Completion data | Result |
|---|---|---|---|---|---|---|
| NCT03460782 | GBM, glioma | SOC + ipilim | Avail | Phase I | Feb. 2019 | Unknown |
| NCT02829931 | Recurrent HGG | Hypofractionated stereotactic irradiation with nivol, ipilim and bevaciz | Recruit | Phase I | Apr. 2021 | Unfinished |
| NCT03425292 | Newly diagnosed HGG | SOC + nivol, ipilim, and bevaciz | Recruit | Phase I | Feb. 2022 | Unfinished |
| NCT03233152 | Recurrent GBM | Intra-tumoral ipilim plus intravenous nivol | Recruit | Phase I | Nov. 2019 | Unfinished |
| NCT03430791 | Recurrent GBM | TTF, nivol and ipilim | Recruit | Phase II | Aug. 2021 | Unfinished |
| NCT03367715 | Newly diagnosed MGMT unmethylated GBM | Nivol, ipilim and short course radiation therapy | Recruit | Phase II | Jan. 2020 | Unfinished |
| NCT02311920 | Newly diagnosed GBM or gliosarcoma | Ipilim, nivol, or both in combination with TMZ | Active, not Recruit | Phase I | Nov. 2018 | Finished |
| NCT02017717 | GBM | Nivol or nivol in combination with ipilim | Active, not Recruit | Phase III | Apr. 2019 | Finished |
| NCT02794883 | GBM | Tremelim and durval | Active, not Recruit | Phase II | Jun. 2020 | Unfinished |
| NCT03707457 | Recurrent GBM | Nivol with anti-GITR monoclonal antibody MK-4166, IDO1 inhibitor INCB024360 or ipilim | Recruit | Phase I | Feb. 2024 | Unfinished |
| NCT03422094 | Newly diagnosed unmethylated GBM | Personalized neoantigen-based vaccine plus poly-ICLC (NeoVax) combined with ICIs | Recruit | Phase I | Apr. 2019 | Unfinished |
aGBM, glioblastoma; HGG, high grade glioma; SOC, standard of care; ipilim, ipilimumab; nivol, nivolumab; bevaciz, bevacizumab; TTF, tumor treating fields; TMZ, temozolomide; tremelim, tremelimumab; durval, durvalumab; Avail, available; Recruit, recruiting.